Research Advance in the Efficacy and Mechanism of Qing Fei Xiao Yan Wan for the Treatment of Respiratory Diseases

DOI: 10.4236/mri.2014.33014   PDF   HTML     3,053 Downloads   3,964 Views  


Qing Fei Xiao Yan Wan had been incorporated into the existing “Chinese Pharmacopoeia”, protected by patents. The manufacturing process of it was scientific and its compatibility was reasonable. It was also shown by clinical trials that the efficacy is exact. Clinical trials and experiment studies had confirmed the efficacy and some mechanism for the treatment of respiratory diseases, which were summaried in this paper. Combined with the experimental results (published in another paper), the other prospect application was further discussed.

Share and Cite:

Ding, J. and Liu, Q. (2014) Research Advance in the Efficacy and Mechanism of Qing Fei Xiao Yan Wan for the Treatment of Respiratory Diseases. Modern Research in Inflammation, 3, 113-121. doi: 10.4236/mri.2014.33014.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Zhou, J., Gao, G., Chu, Q., et al. (2014) Chromatographic Isolation of Nanoparticles from Ma-Xing-Shi-Gan-Tang Decoction and Their Characterization. Journal of Ethnopharmacology, 151, 1116-1123.
[2] Hsieh, C.F., Lo, C.W., Liu, C.H., et al. (2012) Mechanism by Which Ma-Xing-Shi-Gan-Tang Inhibits the Entry of Influenza Virus. Journal of Ethnopharmacology, 143, 57-67.
[3] Luo, H., Wang, Y., Li, Y., et al. (2009) HPLC Determination of Ephedrine Hydrochloride Content in Qingfei Xiaoyan Pill. World Science and Technology/Modernization of Traditional Chinese Medicine and Materia Medica, 11, 461-464.
[4] Wang, Q., Luo, Y., Jin, C., et al. (2008) Effects of Different Drying Methods and Conditions on Anthraquinones and Tannins in Water Extract from Radix et Rhiroma Rhei. Zhong Guo Zhong Yao Za Zhi, 33, 893-896.
[5] Hu, X., Li, W.D., Li, O., et al. (2012) Effect of Gas-Turbine Green Discoloring and Drying Processing Methods on Herbal Quality of Tetraploid Lonicerae Japonicae Flos. Zhong Guo Zhong Yao Za Zhi, 37, 2554-2557.
[6] Li, L.M. and Zhu, Y. (2012) Effects of Complement Inhibiting Component of Ephedra sinica on Immunological Inflammation Following Acute Spinal Cord Injury in Rats. Zhong Guo Zhong Xi Yi Jie He Za Zhi, 32, 1385-1389.
[7] Song, M.K., Um, J.Y., Jang, H.J., et al. (2012) Beneficial Effect of Dietary Ephedra sinica on Obesity and Glucose Intolerance in High-Fat Diet-Fed Mice. Experimental and Therapeutic Medicine, 3, 707-712.
[8] Ikarashi, N., Ogiue, N., Toyoda, E., et al. (2013) Elucidating the Mechanism by Which Gypsum Fibrosum, A Traditional Chinese Medicine, Maintains Cutaneous Water Content. Biological Pharmaceutical Bulletin, 36, 1615-1621.
[9] Ikarashi, N., Ogiue, N., Toyoda, E., et al. (2012) Gypsum Fibrosum and Its Major Component CaSO4 Increase Cutaneous Aquaporin-3 Expression Levels. Journal of Ethnopharmacology, 139, 409-413.
[10] Tanaka, R., Nitta, A. and Nagatsu, A. (2014) Application of a Quantitative (1) H-NMR Method for the Determination of Amygdalin in Persicae Semen, Armeniacae Semen, and Mume Fructus. Journal of Natural Medicines, 68, 225-230.
[11] Jia, J.J., Zeng, X.S., Li, Y., Ma, S. and Bai, J. (2013) Ephedrine Induced Thioredoxin-1 Expression through β-Adrenergic Receptor/Cyclic AMP/Protein Kinase A/Dopamine- and Cyclic AMP-Regulated Phosphoprotein Signaling Pathway. Cellular Signalling, 25, 1194-1201.
[12] Cheng, B.F., Hou, Y.Y., Wang, L.Q., Dong, L.Y., Peng, J.M. and Bai, G. (2012) Dual-Bioactivity-Based Liquid Chromatography-Coupled Quadrupole Time-of-Flightmassspec-Trometry for NF-κB Inhibitors and β2AR Agonists Identification in Chinese Medicinal Preparation Qingfei Xiaoyan Wan. Analytical and Bioanalytical Chemistry, 404, 2445-2452.
[13] Xu, Z., Ju, J., Wang, K., Gua, C.C. and Feng, Y. (2014) Evaluation of Hypoglycemic Activity of Total Lignans from Fructus arctii in the Spontaneously Diabetic Goto-Kakizaki Rats. Journal of Ethnopharmacology, 151, 548-555.
[14] Lee, H.D. and Chiu, H.H. (2012) A Case of Unilateral Pleural Effusion Secondary to Congestive Heart Failure Successfully Treated with Traditional Chinese Herbal Formulas. Journal of Alternative and Complementary Medicine, 18, 509-512.
[15] He, K.B., Wang, Y.Z., Feng, A.L., Duan, F.P., Li, C.X. and Sun, X.Y. (2013) Preparation of Kushen-Dilong Nanoemulsion Gel and Transdermal Characterization in Vitro. Zhong Guo Zhong Yao Za Zhi, 38, 2623-2627.
[16] Ma, H.Y., Zhou, J., Jiang, J.J., Duan, J., Xu, H.Q., Tang, Y.P., Lv, G.H., Zhang, J.F., Zhan, Z. and Ding, A.W. (2012) The Novel Antidote Bezoar Bovis Prevents the Cardiotoxicity of Toad (Bufo bufo gargarizans Canto) Venom in Mice. Experimental and Toxicologic Pathology, 64, 417-423.
[17] Shimizu, Y., Suzuki, T., Oda, K. and Morishita, S. (1999) Pharmacological Studies of Reiousan, a Drug Containing Bezoar and Ginseng—Effects on the Blood Rheology. Yakugaku Zasshi, 119, 731-741.
[18] Liu, Y., Zhang, G.J. and Sun, S.Q. (2010) Study on Rapid Identification of Cornu Saigae Tataricae and Cornu Antelopis Block by Fourier Transform Infrared Spectroscopy. Guang Pu Xue Yu Guang Pu Fen Xi, 30, 42-44.
[19] Zhang, X., Pang, H.L. and Yu, X.H. (2013) Evaluation on the Clinical Application of Qingfei Anti-Inflammatory Pills. Evaluation and Analysis of Drug-Use in Hospitals of China, 13, 780-781.
[20] Zhao, Z.Y., Miao, Y.B., Pan, P.W., Cheng, B.F., Bai, G. and Wu, H. (2013) Qingfei Xiaoyan Wan Alleviates Asthma through Multi-Target Network Regulation. BMC Complementary and Alternative Medicine, 13, 206.
[21] Cheng, B.F., Hou, Y.Y., Jiang, M., Zhao, Z.Y., Dong, L.Y. and Bai, G. (2013) Anti-Inflammatory Mechanism of Qingfei Xiaoyan Wan Studied with Network Pharmacology. Yao Xue Xue Bao, 48, 686-693.
[22] Ren, D. (2011) Antitussive Qing Fei Xiao Yan Wan Is Safer. Kai JuanYou Yi (Qiu Yi Wen Yao), 12, 26.
[23] Bollu, V., Ernst, F.R., Karafilidis, J., Rajagopalan, K., Robinson, S.B. and Braman, S.S. (2013) Hospital Readmissions Following Initiation of Nebulized Arformoterol Tartrate or Nebulized Short-Acting Beta-Agonists among Inpatients Treated for COPD. International Journal of Chronic Obstructive Pulmonary Disease, 8, 631-639.
[24] Spina, D. (2014) Current and Novel Bronchodilators in Respiratory Disease. Current Opinion in Pulmonary Medicine, 20, 73-86.
[25] Seth, H.D., Sultan, S. and Gotfried, M.H. (2013) Role of Indacaterol, a Once-Daily Bronchodilator, in Chronic Obstructive Pulmonary Disease. Journal of Thoracic Disease, 5, 806-814.
[26] Hoza, J., Salzman, R., Starek, I., Schalek, P. and Kellnerova, R. (2013) Efficacy and Safety of Erdosteine in the Treatment of Chronic Rhinosinusitis with Nasal Polyposis—A Pilot Study. Rhinology, 51, 323-327.
[27] Theron, A.J., Steel, H.C., Tintinger, G.R., Feldman, C. and Anderson, R. (2013) Can the Anti-Inflammatory Activities of β2-Agonists Be Harnessed in the Clinical Setting. Drug Design, Development and Therapy, 7, 1387-1398.
[28] Beigel, J. and Bray, M. (2008) Current and Future Antiviral Therapy of Severe Seasonal and Avian Influenza. Antiviral Research, 78, 91-102.
[29] Chen, D., Zhang, F.B., Tang, S.H., Chen, Y., Lu, P., Wen, S.X., et al. (2013) A Network-Based Systematic Study for the Mechanism of the Treatment of Zhengs Related to Cough Variant Asthma. Evidence-Based Complementary and Alternative Medicine, 2013, Article ID: 595924.
[30] Shao, S.J., Quan, C.F., Shao, S.X., Zhou, M., Jing, X.J., Zhao, Y.X., Ren, Z.X., Wang, P.Y., Gao, X.Y., Yang, J., Ren, Z. and Kong, L. (2013) Asthma at Acute Attack Stage Treated with “Shao’s Five Needling Therapy”: A Multi-Central Randomized Controlled Study. Zhong Guo Zhen Jiu, 33, 774-778.
[31] Ren, D. (2012) How to Deal with “Lung Fire” in Spring. Kai Juan You Yi, 3, 34.
[32] Obuchi, M., Adachi, Y., Takizawa, T. and Sata, T. (2013) Influenza A(H1N1)pdm09 Virus and Asthma. Frontiers in Microbiology, 4, 307.
[33] Tsukagoshi, H., Ishioka, T., Noda, M., Kozawa, K. and Kimura, H. (2013) Molecular Epidemiology of Respiratory Viruses in Virus-Induced Asthma. Frontiers in Microbiology, 4, 278.
[34] Kimura, H., Yoshizumi, M., Ishii, H., Oishi, K. and Ryo, A. (2013) Cytokine Production and Signaling Pathways in Respiratory Virus Infection. Frontiers in Microbiology, 4, 276.
[35] Khattab, A., Shaheen, M., Kamel, T., El Faramay, A., Abd El Rahman, S., Nabil, D. and Gouda, M. (2013) Burden of Pediatric Influenza A Virus Infection Post Swine-Flu H1N1 Pandemic in Egypt. Asian Pacific Journal of Tropical Medicine, 6, 693-698.
[36] Green, M.E., Wong, S.T., Lavoie, J.G., Kwong, J., MacWilliam, L., Peterson, S., Liu, G.Y. and Katz, A. (2013) Admission to Hospital for Pneumonia and Influenza Attributable to 2009 Pandemic A/H1N1 Influenza in First Nations Communities in Three Provinces of Canada. BMC Public Health, 13, 1029.
[37] Pohl, J.B., Mayet, A., Beubourg, G., Duron, S., Michel, R., Deparis, X., et al. (2014) The 2009 A(H1N1) Influenza Pandemic in the French Armed Forces: Epidemiological Surveillance and Operational Management. Military Medicine, 179, 183-189.
[38] Wang, J., Shu, J.Z. and Chen, X.Y. (2013) The Effect of PM2.5 Carrier Components on Respiratory Health. Zhong Hua Jie He He Hu Xi Za Zhi, 36, 970-972.
[39] Fu, M.N., Zheng, Y.F., Xu, X.S. and Niu, L. (2011) Advances of Study on Monitoring and Evaluation of PM2.5. Meteorology and Disaster Reduction Research, 34, 1-6.
[40] Li, W., Mao, B., Wang, G., Wang, L., Chang, J., Zhang, Y., Wan, M.H. and Guo, J. (2008) A Study of the Mechanism of Qingre Huatan Therapy in Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease by Improving Airway Inflammation and Mucus Hypersecretion. Zhong Xi Yi Jie He Xue Bao, 6, 799-805.
[41] Li, J.S., Li, S.Y., Xie, Y., Yu, X.Q., Wang, M.H., Sun, Z.K., et al. (2013) The Effective Evaluation on Symptoms and Quality of Life of Chronic Obstructive Pulmonary Disease Patients Treated by Comprehensive Therapy Based on Traditional Chinese Medicine Patterns. Complementary Therapies in Medicine, 21, 595-602.
[42] Ren, D. (2012) Qing Fei Xiao Yan Wan Had Good Effect on Clearing away the Lung-Heat. Kai Juan You Yi, 9, 30.
[43] Zhang, Y., Xiao, W., Jiang, Y., Wang, H., Xu, X., Ma, D., Chen, H. and Wang, X. (2012) Levels of Components of the Urokinase-Type Plasminogen Activator System Are Related to Chronic Obstructive Pulmonary Disease Parenchymal Destruction and Airway Remodelling. Journal of International Medical Research, 40, 976-985.
[44] Vlahos, R. and Bozinovski, S. (2014) Recent Advances in Pre-Clinical Mouse Models of COPD. Clinical Science, 126, 253-265.
[45] Sohal, S.S., Ward, C., Danial, W., Wood-Baker, R. and Walters, E.H. (2013) Recent Advances in Understanding Inflammation and Remodeling in the Airways in Chronic Obstructive Pulmonary Disease. Expert Review of Respiratory Medicine, 7, 275-288.
[46] Rab, A., Rowe, S.M., Raju, S.V., Bebok, Z., Matalon, S. and Collawn, J.F. (2013) Cigarette Smoke and CFTR: Implications in the Pathogenesis of COPD. American Journal of Physiology-Lung Cellular and Molecular Physiology, 305, L530-L541.
[47] Huang, C.P., Xie, M.Y., He, X.H. and Gao, H. (2013) Activity of Sputum p38 MAPK Is Correlated with Airway Inflammation and Reduced FEV1 in COPD Patients. Medical Science Monitor, 19, 1229-1235.
[48] Shen, L.L., Liu, Y.N., Shen, H.J., Wen, C., Jia, Y.L., Dong, X.W., Jin, F., Chen, X.P., Sun, Y. and Xie, Q.M. (2014) Inhalation of Glycopyrronium Inhibits Cigarette Smoke-Induced Acute Lung Inflammation in a Murine Model of COPD. International Immunopharmacology, 18, 358-364.
[49] L?kke, A., Hilberg, O., Tonnesen, P., Ibsen, R., Kjellberg, J. and Jennum, P. (2014) Direct and Indirect Economic and Health Consequences of COPD in Denmark: A National Register-Based Study: 1998-2010. BMJ Open, 4, Article ID: e004069.
[50] Camp, P., Reid, W.D., Yamabayashi, C., Brooks, D., Goodridge, D., Chung, F., Marciniuk, D.D., Neufeld, A. and Hoens, A. (2013) Safe and Effective Prescription of Exercise in Acute Exacerbations of Chronic Obstructive Pulmonary Disease: Rationale and Methods for an Integrated Knowledge Translation Study. Canadian Respiratory Journal, 20, 281-284.
[51] Reissmann, H.K., Ranieri, V.M., Goldberg, P. and Gottfried, S.B. (2000) Continuous Positive Airway Pressure Facilitates Spontaneous Breathing in Weaning Chronic Obstructive Pulmonary Disease Patients by Improving Breathing Pattern and Gas Exchange. Intensive Care Medicine, 26, 1764-1772.
[52] Liu, E., Sun, Z.T., Li, Y.Y., et al. (2010) AECOPD (Phlegm Obstruct the Lung) Clinical Observation on 120 Cases of Qingfei Xiaoyan Wan. Chinese Medicine Modern Distance Education of China, 8, 149-150.
[53] Li, D.S. and Gao, S. (2003) Clinical Observation on Acute Exacerbation of Chronic Bronchitis Treated by Integrative Medicine. Tianjin Journal of Traditional Chinese Medicine, 20, 41.
[54] Yang, Y., Wang, S.C. and Li, R.L. (2010) Effect of Qingkailing Injection on Children with Respiratory Syncytial Virus Pneumonia of Phlegm-Heat Obstructing Fei Syndrome Pattern at Different Time-Points. Zhong Guo Zhong Xi Yi Jie He Za Zhi, 30, 908-911.
[55] Zhao, X.M. (2007) Clinical Observation on Children with Viral Pneumonia Treated by Qingfei Xiaoyan Wan Combined with Western Medicine. Chinese Traditional and Herbal Drugs, 37, 1384-1385.
[56] Bai, F., Rong, Z.D., Bai, G., et al. (2012) Researches on Antibacterial Activity of Qingfei Xiaoyan Wan in Vitro. Drug Evaluation Research, 35, 106-108.
[57] Hou, Y.Y., Li, R.J., Shi, Q., Cheng, B., Wang, L. and Bai, R. (2009) Investigation of the Anti-asthmatic Mechanism of Qing Fei Xiao Yan Wan. Acta Scientiarum Naturalium Universitatis Nankaiensis, 42, 103-107.
[58] Hou, Y.Y., Li, R.J., Cheng, B.F., et al. (2010) Function Study on Clearing Asthma of Qingfei Xiaoyan Wan in Guinea Pigs. Drug Evaluation Research, 33, 103-105.
[59] Qian, L., Wu, H.M., Chen, S.H., Zhang, D., Ali, S.F., Peterson, L., Wilson, B., Lu, R.B., Hong, J.S. and Flood, P.M. (2011) β2-Adrenergic Receptor Activation Prevents Rodent Dopaminergic Neurotoxicity by Inhibiting Microglia via a Novel Signaling Pathway. Journal of Immunology, 186, 4443-4454.
[60] Ueki, T., Akaishi, T., Okumura, H. and Abe, K. (2012) Extract from Nandina domestica Inhibits LipopolysaccharideInduced Cyclooxygenase-2 Expression in Human Pulmonary Epithelial A549 Cells. Biological and Pharmaceutical Bulletin, 35, 1041-1047.
[61] Holden, N.S., George, T., Rider, C.F., Chandrasekhar, A., Shah, S., Kaur, M., et al. (2014) Induction of Regulator of G-Protein Signaling 2 Expression by Long-Acting β2-Adrenoceptor Agonists and Glucocorticoids in Human Airway Epithelial Cells. Journal of Pharmacology and Experimental Therapeutics, 348, 12-24.
[62] Liu, X.R., Tan, W., Liu, Y., Lin, G.P. and Xie, C.M. (2013) The Role of the β2 Adrenergic Receptor on Endothelial Progenitor Cells Dysfunction of Proliferation and Migration in Chronic Obstructive Pulmonary Disease Patients. Expert Opinion on Therapeutic Targets, 17, 485-500.
[63] Baloglu, E., Ke, A., Abu-Taha, I.H., B?rtsch, P. and Mairb?url, H. (2009) In Vitro Hypoxia Impairs β2-Adrenergic Receptor Signaling in Primary Rat Alveolar Epithelial Cells. American Journal of Physiology-Lung Cellular and Molecular Physiology, 296, L500-L509.
[64] Fidzinski, P., Salvador-Silva, M., Choritz, L., Geibel, J. and Coca-Prados, M. (2004) Inhibition of NHE-1 Na+/H+ Exchanger by Natriuretic Peptides in Ocular Nonpigmented Ciliary Epithelium. American Journal of Physiology-Cell Physiology, 287, C655-C663.
[65] Kankavi, O., Ata, A. and Gungor, O. (2007) Surfactant Proteins A and D in the Genital Tract of Mares. Animal Reproduction Science, 98, 259-270.
[66] Chen, Q., Jin, M., Yang, F., Zhu, J.H., Xiao, Q.Z. and Zhang, L. (2013) Matrix Metalloproteinases: Inflammatory Regulators of Cell Behaviors in Vascular Formation and Remodeling. Mediators of Inflammation, 2013, Article ID: 928315.
[67] Lee, I.T. and Yang, C.M. (2013) Inflammatory Signalings Involved in Airway and Pulmonary Diseases. Mediators of Inflammation, 2013, Article ID: 791231.
[68] Kucukguven, A. and Khalil, R.A. (2013) Matrix Metalloproteinases as Potential Targets in the Venous Dilation Associated with Varicose Veins. Current Drug Targets, 14, 287-324.
[69] Knapinska, A. and Fields, G.B. (2012) Chemical Biology for Understanding Matrix Metalloproteinase Function. Chembiochem, 13, 2002-2020.
[70] Halade, G.V., Jin, Y.F. and Lindsey, M.L. (2013) Matrix Metalloproteinase (MMP)-9: A Proximal Biomarker for Cardiac Remodeling and a Distal Biomarker for Inflammation. Pharmacology & Therapeutics, 139, 32-40.
[71] Martins, V.L., Caley, M. and O’Toole, E.A. (2013) Matrix Metalloproteinases and Epidermal Wound Repair. Cell and Tissue Research, 351, 255-268.
[72] Wieczorek, E., Reszka, E., Gromadzinska, J. and Wasowicz, W. (2012) Genetic Polymorphism of Matrix Metalloproteinases in Breast Cancer. Neoplasma, 59, 237-247.
[73] Lagente, V., Manoury, B., Nenan, S., Le Quément, C., Martin-Chouly, C. and Boichot, E. (2005) Role of Matrix Metalloproteinases in the Development of Airway Inflammation and Remodeling. Brazilian Journal of Medical and Biological Research, 38, 1521-1530.
[74] Yao, H., Hwang, J.W., Sundar, I.K., Friedman, A.E., McBurney, M.W., Guarente, L., et al. (2013) SIRT1 Redresses the Imbalance of Tissue Inhibitor of Matrix Metalloproteinase-1 and Matrix Metalloproteinase-9 in the Development of Mouse Emphysema and Human COPD. American Journal of Physiology-Lung Cellular and Molecular Physiology, 305, L615-L624.
[75] Muroski, M.E., Roycik, M.D., Newcomer, R.G., Van den Steen, P.E., Opdenakker, G., Monroe, H.R. and Sahab, Z.J. (2008) Matrix Metalloproteinase-9/Gelatinase B Is a Putative Therapeutic Target of Chronic Obstructive Pulmonary Disease and Multiple Sclerosis. Current Pharmaceutical Biotechnology, 9, 34-46.
[76] van Diemen, C.C., Postma, D.S., Siedlinski, M., Blokstra, A., Smit, H.A. and Boezen, H.M. (2011) Genetic Variation in TIMP1 but Not MMPs Predict Excess FEV1 Decline in Two General Population-Based Cohorts. Respiratory Research, 12, 57.
[77] Riggins, K.S., Mernaugh, G., Su, Y., Quaranta, V., Koshikawa, N., Seiki, M., Pozzi, A. and Zent, R. (2010) MT1MMP-Mediated Basement Membrane Remodeling Modulates renal Development. Experimental Cell Research, 316, 2993-3005.
[78] Polimeni, M., Valente, E., Ulliers, D., Giribaldi, G., Prato, M., Opdenakker, G., et al. (2013) Natural Haemozoin Induces Expression and Release of Human Monocyte Tissue Inhibitor of Metalloproteinase-1. PLoS ONE, 8, Article ID: e71468.
[79] Xin, X.F., Zhao, M., Li, Z.L., Song, Y. and Shi, Y. (2007) Metalloproteinase-9/Tissue Inhibitor of Metalloproteinase-1 in Induced Sputum in Patients with Asthma and Chronic Obstructive Pulmonary Disease and Their Relationship to Airway Inflammation and Airflow Limitation. Zhong Hua Jie He He Hu Xi Za Zhi, 30, 192-196.
[80] Liu, E., Liu, W., Sun, Z.T., Su, J.S. and Guan, P. (2013) Effect of Qingfei Xiaoyan Pills on the Expression of MMP-9 and TIMP-1 in the Lung Tissue of COPD Rats. World Chinese Medicine, 8, 649-651.
[81] Liu, W., Sun, Z.T., Liu, E., et al. (2010) Research on Qingfei Xiaoyan Wan Mechanism of COPD Acute Exacerbation in Rats. Chinese Medicine Modern Distance Education of China, 8, 156-157.
[82] Bolser, D.C. (1996) Mechanisms of Action of Central and Peripheral Antitussive Drugs. Pulmonary Pharmacology, 9, 357-364.

comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.